Author

Tracey L. Hlucky

Observed name: Tracey Hlucky

Institutions: Vitalant, Kite Pharma (United States)

Observed institutions: Vitalant, Kite Pharma (United States)

ORCID: 0009-0004-2354-4825

Observed ORCID: 0009-0004-2354-4825

OpenAlex ID: A5028098317

Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies

2023 · Sarah Nikiforow, Matthew J. Frigault, et al. · Transplantation and Cellular Therapy · 32

Risk-Based Qualification of Cellular Starting Material Collection Sites: Tools to Determine Scope of Manufacturer Audits and Reduce Duplicative Efforts

2024 · Peter Holman, Kara Wacker, et al. · Transplantation and Cellular Therapy · 5

Ensuring quality in the community setting by leveraging accreditation

2026 · James Wade Atkins, Karishma Contractor, et al. · Transfusion

Thought leadership in cellular starting material: A review of summary themes from the AABB cellular starting material forums of 2021–2024

2026 · Linda S. Barnes, Priya Baraniak, et al. · Transfusion

Works count: 4

Citation count: 37

H-index: 2

I10-index: 1